NAFDAC Recalls Substandard Astamocil, Astamentin Antibiotics From Market

The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a recall notice for two batches of locally manufactured antibiotics.

The drugs involved are Astamocil (Amoxicillin Suspension 125mg/5ml), Batch No. 826024, and Astamentin (Amoxicillin/Clavulanic Acid Suspension), Batches No. 0503024 and 0501724, both produced by Sam-Ace Ltd in Nigeria.

The agency announced the recall on its official X handle following findings from recent surveillance and laboratory tests, which revealed that both products failed due to low active pharmaceutical ingredient (API) content. This raises concerns about their safety and efficacy.

The medicines are commonly used to treat bacterial infections such as sinusitis, pneumonia, ear infections, and urinary tract infections.

NAFDAC advised consumers, healthcare providers, and distributors to exercise caution, avoid purchasing or using the identified substandard medicines, and report any suspicions of their sale or use to the nearest NAFDAC office or via email at [email protected].

The agency added that it was actively working to remove the affected batches from circulation to safeguard public health.